Antoine Papiernik

By the way, you know, Rona is a lost whale for us because we actually picked... I was going to get to that.

Yeah, we picked Verona as one we had conviction on.

And, you know, hindsight tells us we sold far too early our shares.

But it is what it is.

You know, we made the right call.

But, you know, in that particular case, we were not patient enough.

In the case of Adidax, we were and we, you know, we ripped the benefits down.

Look at Abivax.

Abivax did what it had to do.

And I think what every company needs to do is bring the management that will allow you to look forward and convince the next generations of investors to invest and also to operate as you should.

Marc de Geidel did a lot of his career in the US.

He's also a very known entity to us because I mentioned about Sincor.

He was the CEO of Sincor, selling the company to AstraZeneca.

Before that, he was our CEO in Corvidia, selling it to Nuvo Nordisk.

So three times, by the way, he's the first guy.

I can't remember when is the last time he came to our office.

We have this

basically portraits of our entrepreneurs in our corridor, a wall of fame, as we call it.

And he's the first guy who will have three portraits for having generated returns.

Yeah, of course.